Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Candesartan on Brain Natriuretic Peptide Levels in Subjects With Chronic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.~* Stable, symptomatic New York Heart Association II-IV Chronic Heart Failure with Left Ventricular Ejection Fraction less than or greater than or greater than or equal to 40% treated with standard therapy including Angiotensin Converting Enzyme-inhibitors and/or beta-blockers. Patients with Left Ventricular Ejection Fraction greater than or equal to 40% had to be hospitalized for cardiovascular events during the past 12 months.~Exclusion Criteria:~* History of prior treatment with Angiotensin-Receptor Blockers within two weeks from first.~* Severe or malignant hypertension (Systolic Blood Pressure / Diastolic Blood Pressure greater than 180/110 mmHg).~* Symptomatic hypotension.~* Acute myocardial infarction within one month from first visit.~* Stroke or transient ischemic attack within one month from first visit.~* Percutaneous transluminal coronary angioplasty or coronary artery by-pass graft within one month from first visit.~* Hemodynamically relevant arrhythmias.~* Implant of pacemakers, cardiac resynchronization therapy or cardioverters within 6 months prior the randomization.~* Hemodynamically relevant cardiac valvular defect.~* Constrictive pericarditis or active myocarditis.~* Likelihood of cardiac surgical intervention (of any type) during the overall treatment period.~* Evidence of angina pectoris in the previous month.~* Poorly controlled diabetes mellitus (glycemia greater than 140mg/mL or glycosylated hemoglobin greater than 8% obtained within three months from the study initiation).~* Untreated thyroid dysfunction.~* Renal artery stenosis.~* Angioedema of any etiology.~* Significant liver (aspartate aminotransferase, alanine aminotransferase, total bilirubin or alkaline phosphatase greater than twice the upper limit of normal range) or renal (serum creatinine greater than 2.0 mg/dL or serum potassium greater than 5.0 mmol/L) impairment.~* Anemia of any etiology (defined as hemoglobin levels less than 10.5 g/dL) or any other clinically relevant hematological disease.~* Any disease with malabsorption.~* Presence of any non-cardiac (e.g. cancer) disease that is likely to significantly (i.e. below 1 year from randomization) shorten life expectancy.~* History of chronic alcohol or drug/substance abuse, or presence of other conditions potentially able to affect study subjects' compliance.~* Known allergy, sensitivity or intolerance to study drugs and/or study drugs' formulation ingredients.~* Participation in another trial in the month preceding study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Candesartan QD (Type: EXPERIMENTAL): None
- Standard chronic heart disease therapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).